-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Prostate cancer affects 1 in 8 men, making it the most common cancer in men
"We're about 50 years behind on breast cancer treatment," said Srinivas Vourganti, MD, a urologist at Rush University Medical Center
Men with early-stage or low-risk prostate cancer can adopt a "watch and wait" strategy, which involves regular monitoring of the cancer but no immediate intervention to avoid a more aggressive approach
"A lot of people want to find a middle ground between those two options," Vourganti said
New NanoKnife Technology
This "middle ground" is a new treatment from RUSH using NanoKnife, a tool for irreversible electroporation (IRE)
Vourganti recently used the technique on one of his patients, John, who was diagnosed with prostate cancer in February 2021
"It seemed like a good option, mostly because of the collateral damage that other things might have done," John said
how it works
The NanoKnife has four small probes inserted into the tumor, guided by ultrasound and magnetic resonance imaging (MRI)
The surgery is performed under general anesthesia to ensure that the patient cannot move
"People can go home that day," Vourganti said
John underwent surgery in July 2021, which successfully destroyed cancer cells in his prostate
"Because there are no side effects, I've returned to my normal life," John said
NanoKnife Results
Notably, 15 to 20 percent of prostate cancers recur after initial treatment, Vourganti said
"We don't know if it will work for everyone," Vourganti said
A clinical trial investigating NanoKnife in prostate cancer is enrolling patients at the Rush and Mayo Clinic
John said he was pleased with the choice he made after consulting with Vourganti, stressing that Vourganti is committed to finding more options for prostate cancer patients
.
"He was passionate about what he was doing," John said
.
"He thinks it's a good idea to try something before doing something more extreme to help people
.
That doesn't mean it won't come back
.
But it's all relative, you know? I just Go with the flow
.
We have to do something
.
Let's make the best decision based on the options available
.
"
Courtesy of Rush University Medical Center
